Among SGLT2 inhibitors, dapagliflozin was the drug associated with the lowest occurrence of depression-like symptoms compared to non-users of this drug, as confirmed by three statistically significant disproportionality scores ROR [0.543 (0.304–0.971)], EBGM [0.565 (0.343–0.888)] and ERAM [0.573 (0.331–0.870)], from our FAERS analysis. This evidence concerns the gene SLC5A2 and major depressive disorder.